Abstract:BACKGROUND:Real-time quantitative RT-PCR (RQ-PCR) assay has become a vital tool to monitor residual disease of leukemia. However, the complexity and standardization of RQ-PCR should never be overlooked and the results should be interpreted cautiously in clinical conditions. We aimed to assess the methodology of RQ-PCR and its clinical applications in monitoring molecular kinetics of 36 newly diagnosed cases of acute promyelocytic leukemia patients with t (15; 17) from October 2004 to December 2005.METHODS:All the TaqMan probe-based RQ-PCR reactions and analysis were performed on an ABI-PRISM 7,500 platform. The quantitation of PML-RARalpha transcripts was represented by the normalized quotient, that is, PML-RARalpha transcript copies divided by ABL transcript copies. According to induction therapy, the patients were classed into two groups: group 1 (n = 23), three-drug combination including arsenics, all-trans retinoic acid and mitoxantrone; and group 2 (n = 13), two-drug combination from all-trans retinoic acid, arsenics and mitoxantrone.RESULTS:The sensitivity of RQ-PCR was 1 per 10(5) cells and 5 copies of the PML-RARalpha transcript could be reproducibly detected. No false positive results occurred in 40 non-acute promyelocytic leukemia samples. Optimal amplification efficiency could be attained, which was determined by the slope of the standard curves (slope: -3.2 - -3.7). The inter-assay and intra-assay variation coefficients of the method were 1.01% and 0.56% respectively. Although the time to attain hematological complete remission was similar in both groups, the time to achieve molecular remission of group 1 was significantly shorter than that of group 2 (61 days vs 75 days, P = 0.034). The rate of molecular remission within 70 days was higher in group 1 than in group 2 (75.00% vs 38.46%, P = 0.036). Compared with pretreatment, median reduction of the PML-RARalpha transcript before first consolidation therapy differed significantly between group 1 and group 2 (log scale, 3.15 vs 2.31, P = 0.024). Interestingly, we found that PML-RARalpha transcript levels temporarily increased in bone marrow (7 patients) and peripheral blood (22 patients) samples of patients during induction therapy in both groups.CONCLUSIONS:The RQ-PCR assay is reliable for the detection of PML-RARalpha transcripts. Arsenics, all-trans retinoic acid and mitoxantrone triad induction treatment of acute promyelocytic leukemia is superior to two-drug combination induction therapy in terms of the molecular response.

Detection of Pml-Rar Alpha in Patients with Apl During Follow-Up Period

Acute Promyelocytic Leukemia: Clinical Relevance of Two Major PML-RAR Alpha Isoforms and Detection of Minimal Residual Disease by Retrotranscriptase/polymerase Chain Reaction to Predict Relapse.

Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients

Feasibility and clinical significance of real-time quantitative RT–PCR assay of PML-RARα fusion transcript in patients with acute promyelocytic leukemia

Detecting PML-RARα Transcript in Acute Promyelocytic Leukemia Using Real-Time Quantitative RT-PCR

[Detection of PML/RARalpha Gene Transcripts in 46 Newly Diagnosed Acute Promyelocytic Leukemia Patients by Real-Time Quantitative Reverse-Transcription Polymerase Chain Reaction].

Occurrence of Distinct PML-RAR-alpha Fusion Gene Isoforms in Patients with Acute Promyelocytic Leukemia Detected by Reverse Transcriptase/polymerase Chain Reaction.

Significance of kinetic detection of the PML-RARα fusion gene in children with acute promyelocytic leukemia

Quantification of PML/RARa transcript after induction predicts outcome in children with acute promyelocytic leukemia

[Molecular responses in acute promyelocytic leukemia patients monitored by real-time quantitative RT-PCR]

Impact of RT-PCR Monitoring on the Long-Term Survival in Acute Promyelocytic Leukemia.

[Long-Term Follow-Up of Treatment Outcome and Prognosis on 46 Children with Acute Promyelocytic Leukemia].

Real-time Quantitative Polymerase Chain Reaction for Dynamic Monitoring of Minimal Residual Disease in Acute Promyelocytic Leukemia after Treatment

Development and validation of a droplet digital PCR assay for the evaluation of PML-RARα fusion transcripts in acute promyelocytic leukemia

Expression of PML-RARα is Up-Regulated During ATRA and Arsenics Combined Induction Without Influence on Long-Term Prognosis of Acute Promyelocytic Leukemia.

Clinical Application of Detection of the Fusion Gene in Acute Promyelocytic Leukemia with Reverse-Transcriptase Real-Time Quantitative PCR

PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study

Clinical analysis of 82 cases of acute promyelocytic leukemia with PML-RARα short isoform in children and adults

Comparison of laboratory characteristics and clinical prognosis of APL with negative and positive PML-RARα gene

[Detection and clinical significance of PML protein expression of acute promyelocytic leukemia cells]

[PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease]